Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Corvus Pharmaceuticals, Inc. (CRVS) had Income from Continuous Operations of $-12.32M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-12.32M |
|
-- |
|
-- |
|
$12.22M |
|
$-12.22M |
|
$-0.10M |
|
$-12.32M |
|
$-12.32M |
|
$-12.32M |
|
|
Income from Continuous Operations |
$-12.32M |
$-12.32M |
|
$-12.32M |
|
$-12.22M |
|
$-12.45M |
|
78.96M |
|
79.74M |
|
$-0.18 |
|
$-0.52 |
|
| Balance Sheet Financials | |
$58.21M |
|
$0.22M |
|
$12.90M |
|
$71.12M |
|
$9.38M |
|
-- |
|
$0.53M |
|
$9.91M |
|
$61.20M |
|
$61.20M |
|
$61.20M |
|
74.70M |
|
| Cash Flow Statement Financials | |
$-32.80M |
|
$-7.80M |
|
$36.43M |
|
$8.74M |
|
$4.58M |
|
$-4.16M |
|
$5.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-32.97M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.13% |
|
-20.13% |
|
-17.32% |
|
-20.13% |
|
$0.82 |
|
$-0.41 |
|
$-0.41 |
|